Literature DB >> 25482866

Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival.

Laura Spring1, Shuli Li1, Robert J Soiffer1, Joseph H Antin1, Edwin P Alyea1, Brett Glotzbecker2.   

Abstract

Patients treated with allogeneic hematopoietic stem cell transplantation (HSCT) are presumed to be at high risk for hospital readmission. The objective of this study was to identify the incidence and associated risk factors for readmissions in allogeneic HSCT patients and to evaluate the effect of readmissions on overall survival. In this retrospective review, we included 1141 HSCT patients (503 patients receiving a myeloablative [MAC] HSCT and 638 a reduced-intensity conditioning [RIC] HSCT). We measured rates of readmission at 30 days after discharge from HSCT and by day +100 after HSCT. Reasons for readmission, risk factors for readmission, and effect on overall survival were assessed. In the MAC group, 130 of 459 (28.3%) patients were readmitted within 30 days of discharge and 195 of 456 (42.8%) patients by day 100. In the RIC group, 105 of 600 (17.5%) patients were readmitted within 30 days of discharge and 185 of 595 (31.1%) patients by day 100. There were significantly more readmissions in the MAC group at both the 30-day (P < .001) and day +100 time points (P < .001). The most frequent reason for readmission was infection (28.2% in MAC group, 27.3% in RIC group). The occurrence of infection during the index admission was the only risk factor significant in both groups at both time points in the multivariable regression analysis. Readmission was significantly associated with decreased overall survival in both groups and at both time points. MAC patients are readmitted significantly more than RIC patients. Infection is the most common cause of readmission after HSCT and the occurrence of infection during the index transplantation admission is a significant risk factor for readmission. Readmission within 30 days of discharge and by day +100 after transplantation was a significant risk factor for a lower 5-year overall survival rate in both groups.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Readmission; Survival

Mesh:

Year:  2014        PMID: 25482866     DOI: 10.1016/j.bbmt.2014.11.682

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

1.  Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation.

Authors:  L Decook; Y-H Chang; J Slack; D Gastineau; J Leis; P Noel; J Palmer; L Sproat; M Sorror; N Khera
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

2.  Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Sagar S Patel; Lisa A Rybicki; Donna Corrigan; Brian Bolwell; Robert Dean; Hien Liu; Aaron T Gerds; Rabi Hanna; Brian Hill; Deepa Jagadeesh; Matt Kalaycio; Brad Pohlman; Ronald Sobecks; Navneet S Majhail; Betty K Hamilton
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-31       Impact factor: 5.742

3.  Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients.

Authors:  Daniel R Richardson; Ying Huang; Heather L McGinty; Patrick Elder; Joanna Newlin; Cyndi Kirkendall; Leslie Andritsos; Don Benson; William Blum; Yvonne Efebera; Sam Penza; Craig Hofmeister; Samantha Jaglowski; Rebecca Klisovic; Sumithira Vasu; Basem William; Steven Devine; Ashley E Rosko
Journal:  Bone Marrow Transplant       Date:  2018-02-14       Impact factor: 5.483

4.  Caregiver availability and patient access to hematopoietic cell transplantation: social worker perspectives inform practice.

Authors:  Jaime M Preussler; Lih-Wen Mau; Navneet S Majhail; Margaret Bevans; Emilie Clancy; Carolyn Messner; Leslie Parran; Kate A Pederson; Stacy Stickney Ferguson; Kent Walters; Elizabeth A Murphy; Ellen M Denzen
Journal:  Support Care Cancer       Date:  2019-03-09       Impact factor: 3.603

5.  Impact of hospital length of stay on the risk of readmission and overall survival after allogeneic stem cell transplantation.

Authors:  Aika Seto; Yoshiko Atsuta; Naomi Kawashima; Yukiyasu Ozawa; Koichi Miyamura; Hitoshi Kiyoi
Journal:  Int J Hematol       Date:  2018-06-19       Impact factor: 2.490

6.  Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting.

Authors:  Noa Granot; Barry E Storer; Jason P Cooper; Mary E Flowers; Brenda M Sandmaier; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2019-06-28       Impact factor: 5.742

7.  Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis.

Authors:  Jifang Zhou; Edith A Nutescu; Jin Han; Gregory S Calip
Journal:  J Cancer Surviv       Date:  2020-01-02       Impact factor: 4.442

Review 8.  Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications.

Authors:  Monica Reis; Justyna Ogonek; Marsela Qesari; Nuno M Borges; Lindsay Nicholson; Liane Preußner; Anne Mary Dickinson; Xiao-Nong Wang; Eva M Weissinger; Anne Richter
Journal:  Front Immunol       Date:  2016-11-14       Impact factor: 7.561

9.  Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia.

Authors:  Myriam Razgallah Khrouf; Leila Achour; Asma Thabti; Mohamed Ali Soussi; Nour Abdejelil; Olfa Lazreg; Chema Drira; Aida Zahaf; Saloua Ladab; Tarek Ben Othman
Journal:  J Mark Access Health Policy       Date:  2017-06-15

10.  Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia-A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP.

Authors:  Herbert Pichler; Anita Lawitschka; Evgenia Glogova; Andre M Willasch; Irene von Luettichau; Thomas Lehrnbecher; Susanne Matthes-Martin; Peter Lang; Peter Bader; Karl W Sykora; Johanna Schrum; Bernhard Kremens; Karoline Ehlert; Michael H Albert; Michaela Kuhlen; Roland Meisel; Tayfun Guengoer; Brigitte Strahm; Bernd Gruhn; Ansgar Schulz; Wilhelm Woessmann; Ulrike Poetschger; Christina Peters
Journal:  Am J Hematol       Date:  2019-05-29       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.